1. A-83-01 Considered A Fighting Component in Cancer Treatment

    In a study on how the ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-β, A-83-01 was synthesized and characterized a small molecule inhibitor. It is structurally similar to previously reported ALK-5 inhibitors developed by Sawyer et al. (2003) and blocks signaling of type I serine/threonine kinase receptors for cytokines of the TGF-β superfamily (known as activin receptor-like kinases; ALKs).

1 Item

To Top